Business/Financial News Archives | Page 36 of 37

MicroCHIPS drums up another $16.5 million and a new investor

January 7, 2010 By drugdelivery

MicroCHIPS Inc. corraled a group of existing investors and roped in a new backer into the fold, adding $16.5 million to its coffers as it works toward bringing its platform monitoring and treatment implant technology to market.

Existing backers Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic (NYSE:MDT), Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital all upped their investment in the Bedford, Mass.-based company. New backer InterWest Partners also chipped in.

Echo Therapeutics gears up for investor push

December 10, 2009 By drugdelivery

Echo Therapeutics Inc. (OTC:ECTE) is gearing up for a push to land new investors next year, which it expects to be “transformative,” hiring a New York-based investor relations consulting firm to manage a “strategic investor relations campaign.”

Hayden IR will develop and implement the Franklin, Mass.-based company’s bid to attract more investors in 2010. Echo is developing needle-free drug delivery technologies, including a non-invasive, wireless glucose monitoring device and skin preparation system for transdermal drug delivery.

MicroCHIPS recognized by world economic forum

December 3, 2009 By drugdelivery

What does MicroCHIPS Inc. have in common with Twitter?

Both were among a pool of 26 firms named 2010 Technology Pioneers by the World Economic Forum in Switzerland. The awards are handed out yearly to companies that are “involved in the development of a life-changing technology innovation and have the potential for long-term impact on business and society.”

The 26 companies were winnowed from a pool of 300 applicants and judged by 58 “experts,” according to the Swiss think tank, from the ranks of academia, media and industry.

Taris Biomedical completes Phase I study of bladder drug-device combo

December 2, 2009 By drugdelivery

Taris Biomedical said it successfully completed the first phase of clinical trials of its drug-device combination to treat bladder problems, but declined to release any details of the study pending scientific publication.

The Lexington, Mass.-based firm said the study of its Liris device, which stands for “lidocaine-releasing intravesical system,” was aimed at evaluating the safety, tolerability and retention of the system in the bladder for treating interstitial cystitis. Also known as painful bladder syndrome, IC involves chronic inflammation of the bladder wall.

Taris Biomedical names new CMO

November 9, 2009 By drugdelivery

Taris Biomedical tapped Julie Lekstrom Himes to be its chief medical officer and lead its clinical development program.

Echo Therapeutics begins clinical study of transdermal glucose monitor

November 4, 2009 By drugdelivery

Echo Therapeutics Inc. will complete a clinical study of its Symphony non-invasive, wireless transdermal continuous glucose monitoring system by the fourth quarter, in what would be a major step forward for a company that has burned through more than $60 million trying to bring its products to market.

MassDevice Q&A: Maggie Pax

October 23, 2009 By Brian Johnson

MicroCHIPS Inc. may have been the result of divine inspiration (as the story goes, MIT professor Robert Langer thought of the idea while watching PBS), but it took people like Maggie Pax to turn his vision into a suite of implantable devices that could one day revolutionize medicine.

MassDevice Q&A: Shawna Gvazdauskas

June 30, 2009 By Brian Johnson

Shawna Gvazdauskas has a knack for bringing medical devices to market. The 53-year-old is on the third start-up of her 30-year career. In March, she left insulin management maker Insulet, where she helped bring the company’s flagship Omnipod to market, for a new challenge at Isis Biopolymer Inc., which is developing a new generation of non-invasive drug delivery patches.

Taris Biomedical launches with $15 million financing round

June 25, 2009 By drugdelivery

Taris Biomedical hit the ground running, raising $15 million from venture fund backers for its launch.

The Lexington-based drug-device developer, which is aiming to leverage lidocaine delivery technology developed at MIT to treat bladder conditions, said (PDF) Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners led the investment round.

UPDATE: Insulet hits the road in Europe after landing EU approval for its OmniPod insulin system

April 28, 2009 By drugdelivery

MassDevice caught Rob Campbell, Insulet Corp.‘s vice president of clinical research, on his way to dinner in Paris after a day spent lining up a distribution deal for the company’s flagship OmniPod insulin management system.

European Union regulators gave the nod for the device to hit the market there, meaning the Bedford-based diabetes device maker is cleared to start selling the OmniPod in countries that recognize the EU’s CE Mark.